



August 14, 2026

**BSE Limited**

Corporate Service Department,  
1<sup>st</sup> Floor, P. J. Towers,  
Dalal Street,  
Mumbai 400 001

**Scrip Code:** 504067

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai 400 051

**Symbol:** ZENSARTECH

**Sub.: Update on Merger of US subsidiaries**

Dear Sir/Madam,

This is in continuation of our letter dated July 29, 2026, wherein we informed you that the Board of Directors of the Company had accorded in-principle approval for the merger of the following US-based 100% step-down subsidiaries with Zensar Technologies Inc., USA, a material wholly owned subsidiary of the Company:

- i. Bridgeview Life Sciences LLC
- ii. M3BI LLC

Further, vide our letter dated July 31, 2026, we informed you that all requisite filings in connection with the merger of Bridgeview Life Sciences LLC with Zensar Technologies Inc. had been completed.

In this regard, we wish to inform you that all requisite filings in connection with the merger of M3BI LLC with Zensar Technologies Inc. were completed with the relevant local authorities/state agencies on August 13, 2026. Accordingly, the merger of M3BI LLC with Zensar Technologies Inc. shall become effective from September 1, 2026. The Company received intimation in this regard at 1:43 a.m. (IST) on August 14, 2026.

With the completion of the aforesaid filing, all requisite filings with the relevant local authorities/state agencies in connection with the mergers of Bridgeview Life Sciences LLC and M3BI LLC with Zensar Technologies Inc. have now been completed. Certain post-merger and consequential filings remain under process and are expected to be completed in due course.

This is for your information and records.

Thanking you,

Yours sincerely,

For **Zensar Technologies Limited**

**Anand Daga**  
**Company Secretary**



An  **RPG** Company